T1	Action 14 19;9 13	score PPID
T2	Concept 4 8	mean
R1	in-context Arg1:T1 Arg2:T2	
T3	Concept 23 33	SARS-CoV-2
T4	Concept 35 40;41 45	Human SARS
T5	Concept 51 54;55 58	Bat CoV
T6	Concept 79 84	1.41%
T7	Action 14 19;9 13	score PPID
R2	subject Arg1:T7 Arg2:T3	
R3	target Arg1:T7 Arg2:T6	
T8	Concept 86 91	1.12%
R4	subject Arg1:T1 Arg2:T4	
R5	target Arg1:T1 Arg2:T8	
T9	Action 14 19;9 13	score PPID
R6	subject Arg1:T9 Arg2:T5	
T10	Concept 97 102	1.85%
R7	target Arg1:T9 Arg2:T10	
T11	Concept 141 152;153 164	generalized circulation
T12	Concept 172 182	SARS-CoV-2
R8	in-context Arg1:T12 Arg2:T11	
T13	Action 190 202	surveillance
T14	Concept 212 220;221 232	clinical description
R9	in-context Arg1:T13 Arg2:T14	
T15	Concept 237 245;249 252	swabbing GPs
R10	in-context Arg1:T13 Arg2:T15	
R11	target Arg1:T13 Arg2:T12	
T16	Action 285 291	assess
R12	subject Arg1:T16 Arg2:T13	
T17	Reference 296 305	situation
R13	target Arg1:T16 Arg2:T17	
T18	Concept 318 328	SARS-CoV-2
T19	Concept 329 337	proteins
R14	in-context Arg1:T19 Arg2:T18	
T20	Concept 329 337	proteins
T21	Concept 394 398	SARS
R15	in-context Arg1:T20 Arg2:T21	
T22	Action 354 357;365 369;370 373	act same way
R16	target Arg1:T22 Arg2:T20	
R17	subject Arg1:T22 Arg2:T20	
T23	Concept 410 419;420 428	accessory proteins
T24	Action 436 445	localized
R18	subject Arg1:T24 Arg2:T23	
T25	Concept 453 464;465 480;481 493;494 505	endoplasmic reticulum-Golgi intermediate compartment
R19	in-place Arg1:T24 Arg2:T25	
R20	is-a Arg1:T19 Arg2:T23	
R21	is-a Arg1:T20 Arg2:T23	
T26	Concept 533 537;538 546	cell membrane
R22	in-place Arg1:T24 Arg2:T26	
T27	Concept 608 623;624 636	protein-protein interactions
T28	Action 572 585	pathogenicity
T29	Action 590 599	mortality
R23	subject Arg1:T28 Arg2:T18	
R24	subject Arg1:T29 Arg2:T18	
R25	causes Arg1:T27 Arg2:T28	
R26	causes Arg1:T27 Arg2:T29	
R27	in-place Arg1:T27 Arg2:T26	
T30	Concept 719 731;732 738	pcMNPs-based method
T31	Concept 675 685	robustness
T32	Concept 691 700;701 713	excellent performances
R28	has-property Arg1:T30 Arg2:T32	
R29	has-property Arg1:T30 Arg2:T31	
T33	Action 743 750	provide
A1	Uncertain T33
T34	Action 823 826;827 837;838 848	RNA extraction operations
R30	subject Arg1:T33 Arg2:T30	
T35	Concept 763 774	alternative
T36	Concept 802 816	time-consuming
R31	in-context Arg1:T34 Arg2:T35	
R32	in-context Arg1:T34 Arg2:T36	
R33	target Arg1:T33 Arg2:T34	
T37	Action 920 929;930 939	molecular diagnosis
T38	Concept 909 919	SARS-CoV-2
R34	target Arg1:T37 Arg2:T38	
R35	subject Arg1:T37 Arg2:T30	
T39	Concept 876 885	potential
R36	in-context Arg1:T37 Arg2:T39	
T40	Concept 948 953;954 962	viral pathogen
T41	Concept 963 973	SARS-CoV-2
R37	is-a Arg1:T41 Arg2:T40	
T42	Action 974 981	emerged
R38	subject Arg1:T42 Arg2:T41	
T43	Concept 985 989;990 994	late 2019
R39	in-time Arg1:T42 Arg2:T43	
T44	Action 1007 1018;1019 1023	exponential rise
R40	causes Arg1:T41 Arg2:T44	
T45	Concept 1081 1086;1090 1098	cases COVID-19
T46	Concept 1099 1106	disease
R41	is-a Arg1:T45 Arg2:T46	
R42	target Arg1:T44 Arg2:T45	
